Johnson & Johnson Reports Q3 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Johnson & Johnson (JNJ) Reports a Beat-and-Raise 3Q, Analyst Positive
October 19, 2021 7:53 AM EDTJohnson & Johnson (NYSE: JNJ) reported better-than-expected 3Q results today and left its vaccine guidance unchanged.
The company reported Q3 EPS of $2.60 to top the analyst estimate of $2.36. However, revenue for the quarter came in at $23.3 billion to miss the consensus estimate of $23.74 billion. The company left its COVID-19 vaccine sales target unchanged at $2.5... More
Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
October 19, 2021 6:27 AM EDT(Updated - October 19, 2021 6:28 AM EDT)
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.60, $0.24 better than the analyst estimate of $2.36. Revenue for the quarter came in at $23.3 billion versus the consensus estimate of $23.74 billion.
GUIDANCE:
Johnson & Johnson sees 2021 EPS of $9.77-$9.82,... More
